Compare BMRN & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRN | TECH |
|---|---|---|
| Founded | 1996 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.9B |
| IPO Year | 1999 | 1989 |
| Metric | BMRN | TECH |
|---|---|---|
| Price | $55.79 | $64.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 14 |
| Target Price | ★ $90.00 | $71.23 |
| AVG Volume (30 Days) | ★ 3.1M | 2.1M |
| Earning Date | 10-27-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 0.50% |
| EPS Growth | ★ 59.53 | N/A |
| EPS | ★ 2.68 | 0.49 |
| Revenue | ★ $3,094,001,000.00 | $1,216,732,000.00 |
| Revenue This Year | $13.32 | $3.64 |
| Revenue Next Year | $7.51 | $7.59 |
| P/E Ratio | ★ $20.86 | $132.53 |
| Revenue Growth | ★ 12.39 | 3.85 |
| 52 Week Low | $50.76 | $46.01 |
| 52 Week High | $73.51 | $79.28 |
| Indicator | BMRN | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 60.07 |
| Support Level | $54.51 | $57.02 |
| Resistance Level | $56.45 | $66.06 |
| Average True Range (ATR) | 1.53 | 2.03 |
| MACD | 0.28 | 0.56 |
| Stochastic Oscillator | 81.90 | 78.76 |
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.